Page 11234..»

Archive for the ‘Stem Cell kidney Failure’ Category

BAME lives to be saved as new organ donation law rolls out – Keep the Faith

Wednesday, January 15th, 2020

You can help support Keep The Faith;Click here to find out how Hundreds of lives will be saved from spring 2020 when the law on organ donation in England changes. The switch means anyone over 18-years-old who dies (with the exception of special groups) will automatically be considered for organ donation this will significantly improve outcomes for minority groups

Read More...

HIV drug resistance an emerging threat, expert warns – DAWN.com

Friday, January 10th, 2020

KARACHI: There is an urgent need for educating people on the means of transmission and prevention of sexually transmitted diseases and address the social stigma and fear attached to HIV/AIDS.

Read More...

A Lasting Legacy: DuPont, C8 Contamination and the Community Left to Grapple With the Consequences – alleghenyfront.org

Friday, January 10th, 2020

Tommy Joyce is no cinephile. The last movie he saw in a theater was the remake of True Grit nearly a decade ago. Id rather watch squirrels run in the woods than sit through most of what appears on the big screen, he said

Read More...

Merck’s KEYTRUDA (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as…

Monday, January 6th, 2020

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-604 trial investigating KEYTRUDA, Mercks anti-PD-1 therapy, in combination with chemotherapy met one of its dual primary endpoints of progression-free survival (PFS) in the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC). In the study, treatment with KEYTRUDA in combination with chemotherapy (etoposide plus cisplatin or carboplatin) resulted in a statistically significant improvement in PFS compared to chemotherapy alone (HR=0.75 [95% CI, 0.61-0.91]), which was observed at a prior interim analysis. At the final analysis of the study, there was also an improvement in overall survival (OS) for patients treated with KEYTRUDA in combination with chemotherapy compared to chemotherapy alone; however, these OS results did not meet statistical significance per the pre-specified statistical plan (HR=0.80 [95% CI, 0.64-0.98])

Read More...

GSK announces positive headline results in phase 3 study of Benlysta in patients with lupus nephritis | Antibodies | News Channels -…

Sunday, December 22nd, 2019

DetailsCategory: AntibodiesPublished on Friday, 20 December 2019 13:14Hits: 658 - BLISS-LN achieves primary endpoint and all major secondary endpoints - On-track for regulatory submission during the first half of 2020 LONDON, UK I December 18, 2019 I GSK today announced positive headline results for intravenous (IV) Benlysta (belimumab) in the largest controlled phase 3 study in active lupus nephritis (LN), an inflammation of the kidneys caused by systemic lupus erythematosus (SLE) which can lead to end-stage kidney disease. The Efficacy and Safety of Belimumab in Patients with Active Lupus Nephritis (BLISS-LN) study, involving 448 patients, met its primary endpoint demonstrating that a statistically significant greater number of patients achieved Primary Efficacy Renal Response (PERR) over two years when treated with belimumab plus standard therapy compared to placebo plus standard therapy in adults with active LN (43% vs 32%, odds ratio (95% CI) 1.55 (1.04, 2.32), p=0.0311). Dr Hal Barron, Chief Scientific Officer and President R&D, GSK said: "Lupus nephritis is one of the most common and serious complications of SLE, occurring in up to 60% of adult patients.

Read More...

Merck’s KEYTRUDA (pembrolizumab) Approved in Japan for Three New First-Line Indications Across Advanced Renal Cell Carcinoma (RCC) and Recurrent or…

Sunday, December 22nd, 2019

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Mercks anti-PD-1 therapy, received new approvals from the Japan Pharmaceuticals and Medical Devices Agency (PMDA) in advanced renal cell carcinoma (RCC) and head and neck cancer for the following additional indications in Japan: Advanced renal cell carcinoma and head and neck cancer have historically been associated with poor outcomes and new treatment options are needed in Japan, said Dr.

Read More...

FDA Grants Accelerated Approval to Astellas’ and Seattle Genetics’ PADCEV (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic…

Sunday, December 22nd, 2019

"Metastatic urothelial cancer is an aggressive and devastating disease with limited treatment options, and the approval of PADCEV is a significant advance for these patients who previously had limited options after initial therapies failed," said Jonathan E. Rosenberg, M.D., Medical Oncologist, Chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center in New York

Read More...

Researchers ID Molecule that Appears to Halt and Reverse Scarring in Fibrotic Diseases – BioSpace

Sunday, December 15th, 2019

Fibrosis, or scarring, is central to a number of diseases, including cirrhosis of the liver, chronic kidney disease and several lung diseases.

Read More...

The Promise of in vitro 3D Organoid Models: Meeting the ADME-Tox Testing Needs of the Pharmaceutical Industry – Technology Networks

Monday, November 18th, 2019

Inadequate prediction of drug metabolism or toxicity is the Achilles heel of the pharmaceutical industry, leading to high drug attrition rates. This can have significant implications for companies, with late-stage failure typically resulting in the loss of substantial financial investments, time and resources

Read More...

Diabetes 1 Breakthrough: Researchers Are Now Able to Create Insulin-Producing Cells – Gilmore Health News

Wednesday, November 6th, 2019

After years of trying, researchers finally were able to transform human stem cells into mature cells that produce insulin.

Read More...

The 2019 Nobel Prize in Medicine awarded for research in cellular responses to oxygen – World Socialist Web Site

Thursday, October 10th, 2019

The 2019 Nobel Prize in Medicine awarded for research in cellular responses to oxygen By Benjamin Mateus 10 October 2019 In the course of a lifetime, the human heart will beat more than three billion times. We will have taken more than 670 million breaths before we reach the end of our lives.

Read More...

Eurecon Verlag GmbH: 20th Pharma Trend Image & Innovation Awards The Winners and Runner-ups – Business Wire

Thursday, October 10th, 2019

MUNICH--(BUSINESS WIRE)--An interdisciplinary jury of ten evaluated the applications by medical startups in the categories biotechnology, medical technology and digital health. The products and projects ranked among the top 3 received the Most Innovative Product Award.

Read More...

Genetics of Kidney Cancer (Renal Cell Cancer) (PDQ …

Wednesday, October 2nd, 2019

More than 55% of VHL-affected individuals develop only multiple renal cell cysts.

Read More...

7 Alternative Kidney Disease Treatments | Stem Cell Research

Friday, September 20th, 2019

Kidney disease treatment is no longer limited to conventional medicine, dialysis, or surgery. Alternative treatments are also available to treat some types of kidney disease and to manage its symptoms. Alternative treatments enhance standard kidney disease treatment.

Read More...

Kidney Failure | Renal Disease | Stem Cell Treatment …

Monday, April 15th, 2019

About Kidney Failure Kidney failure (or renal failure) is a condition in which the kidneys fail to filter waste products from your blood.

Read More...

Stem cell study holds out promise for kidney disease | The …

Monday, April 15th, 2019

Image via youtube.com Kidney failure is the Rodney Dangerfield of diseases, it really doesnt get the respect it deserves. An estimated 660,000 Americans suffer from kidney failure and around 47,000 people die from it every year. Thats more than die from breast or prostate cancer.

Read More...

The kidney repair shop | Harvard Stem Cell Institute (HSCI)

Friday, March 15th, 2019

Regeneration is, of course, the Holy Grail of medicine. Many diseases are chronic because they are a consequence of damage to organs or tissues beyond any natural repair mechanism

Read More...

Funding Clinical Trials | California’s Stem Cell Agency

Tuesday, March 12th, 2019

Mark Humayun University of Southern California Phase 1 Active, not recruiting 16 Tippi MacKenzie University of California, San Francisco Phase 1 Recruiting 10 Ralph Kern BrainStorm Cell Therapeutics Phase 3 Recruiting 200 Clive Svendsen Cedars-Sinai Medical Center Phase 1/2 Active, not recruiting 18 Crystal Mackall Stanford University Phase 1 Recruiting 57 Thomas Kipps University of California, San Diego Phase 1/2 Recruiting 156 Ed Conner Sangamo BioSciences, Inc.

Read More...

Stem Cell Therapy Chicago Illinois, Buffalo Grove …

Friday, March 8th, 2019

TREATMENTS Regenerative revolutionary cord blood stem cell therapies along with PRP therapy that are effective, nonsteroidal, outpatient & repairdamaged tissue.

Read More...

Stem Cell Vet UK Treat Arthritis in Dogs & Cats

Thursday, February 28th, 2019

The procedure is carried out in one day as an outpatient, and patients generally do not need an overnight stay with us. We need some blood tests for anesthetic safety

Read More...

Page 11234..»


2020 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick